A New Prognostic Score Model for Pancreatic Ductal Adenocarcinoma
NCT ID: NCT05547074
Last Updated: 2022-09-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
302 participants
OBSERVATIONAL
2019-09-01
2022-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Precise Gene Signature for Predicting Outcomes in PDAC
NCT05441189
Risk Factors of Postoperative Complications and Survival Rate in Pancreatic Ductal Adenocarcinoma Patients
NCT06378853
Genetic, Microenvironmental, and Immunological Factors in Unresectable Pancreatic Ductal Adenocarcinoma
NCT05248750
Assessment of Early Pancreatic Cancer Prognosis by Minimal Residual Disease Using Multi-omics Approach
NCT06151691
Establishment of a Predictive Model for Immunotherapy Response in Pancreatic Cancer
NCT07271823
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
The training cohort
To develop the prognostic model, 302 cases of postoperative PDAC were included in the final analysis and divided into the training and validation cohort by stratified sampling with 7:3 ratio (The training cohort: n=212; The validation cohort: n=90).
pancreatic cancer surgery
Surgical resection of pancreatic cancer，including radical or palliative surgery
The validation cohort
To develop the prognostic model, 302 cases of postoperative PDAC were included in the final analysis and divided into the training and validation cohort by stratified sampling with 7:3 ratio (The training cohort: n=212; The validation cohort: n=90).
pancreatic cancer surgery
Surgical resection of pancreatic cancer，including radical or palliative surgery
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
pancreatic cancer surgery
Surgical resection of pancreatic cancer，including radical or palliative surgery
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Achievement of surgical resection (including radical or palliative surgery)
Exclusion Criteria
2. Simultaneous presence of other tumors
3. Died in three months after surgery
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zhejiang University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
TingBo Liang
Head of Hepatobiliary and Pancreatic Surgery
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tingbo Liang
Role: PRINCIPAL_INVESTIGATOR
First Affiliated Hospital, Medical College of Zhejiang University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
First Affiliated Hospital, Medical College of Zhejiang University
Hangzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PSMPDAC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.